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Metachromatic leucodystrophy (MLD) is a rare inherited lysosomal disorder caused
by reduced activity of the enzyme arylsulfatase A with accumulation of sulfatides
in the nervous system. We report a female child affected by MLD who developed
central precocious puberty (CPP). This association has not been described so far. The
proposita, after normal growth and psychomotor development, at age of 30 months
presented with a rapidly progressive gait disturbance with frequent falls and with loss
of acquired language skills. Magnetic resonance imaging showed leukoencephalopathy.
Biochemical blood essays showed a 91% reduction in the arylsulfatase A activity and
genetic analysis revealed compound heterozygousmutations of the Arylsulfatase A gene,
enabling diagnosis of MLD. Subsequently, the patient had further rapid deterioration of
motor and cognitive functions and developed drug-resistant epilepsy. At 4 years and 7
months of age bilateral thelarche occurred. Magnetic resonance imaging showed a small
pituitary gland, extensive signal changes of the brain white matter, increased choline,
decreased N-acetyl-aspartate and presence of lactate on 1HMR spectroscopy. Pelvic
ultrasound demonstrated a slightly augmented uterine longitudinal diameter (42mm). The
gonadotropin-releasing hormone stimulation test revealed a pubertal LH peak of 12.9
UI/l. A diagnosis of CPP was made and treatment with gonadotropin-releasing hormone
agonists was initiated, with good response. In conclusion, a CPP may occur in MLD as
in other metabolic diseases with white matter involvement. We hypothesize that brain
accumulation of sulfatides could have interfered with the complex network regulating
with the hypothalamic-pituitary axis and thus triggering CPP in our patient.
Keywords: metachromatic leucodystrophy, central precocious puberty, precocious puberty, metabolic disease,
white matter disease
INTRODUCTION
Metachromatic leucodystrophy (MLD; OMIM #250100) is a rare autosomal recessive inherited
lysosomal disorder, caused by reduced activity of the enzyme arylsulfatase A, due to mutations in
the Arylsulfatase A gene (ARSA; OMIM ∗ 607574) that is located on chromosome 22q13.33 (1, 2).
Rarely, the phenotype is also due to mutations in the Prosaposin gene (PSAP; OMIM ∗ 176801),
encoding an activator of ASA (prosaposin), or in sulfatase-modifying factor-1 gene (SUMF1; OMIM
∗ 607939) (2, 3). Birth prevalence of MLD is estimated between 1.4 e 1.8 per 100.000 (4).
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Arylsulfatase A deficiency results in accumulation of sulfatides
in the central and peripheral nervous system, typically leading
to demyelination of the brain white matter (1). Psychomotor
regression, intellectual and behavioral changes are the main
clinical features of MLD (4, 5).
According to the age of onset, the disease is classified in
three clinical subtypes: (a) late-infantile form (before 30months),
characterized by rapidly progressive psychomotor regression,
ataxia and areflexia; (b) juvenile variant (onset between 2.5 and
16 years of age), often beginning with impaired fine motor skills,
deterioration of school performance or behavior abnormalities;
c) adult onset type (after the age of 16 years), with memory
deficits or emotional instability as the most frequent initial
symptoms (1, 5).
Herein we report the case of a girl affected by MLD who
developed central precocious puberty (CPP). This association
has not been described so far. Written informed consent was
obtained from the parents of the patient for the publication of
this case report.
CASE PRESENTATION
This female child was diagnosed with juvenile variant of
MLD at 2.5 years of age. She had exhibited normal growth
and psychomotor development. At age of 30 months she
presented with progressive gait disturbance with frequent
falls as well as with loss of acquired language skills, which
worsened despite psychomotor rehabilitation. Brain Magnetic
resonance imaging (MRI) revealed a marked and widespread
hyperintensity of white matter in T2 weighted images, consistent
with a leukodystrophy. Biochemical blood essays showed a 91%
reduction in the arylsulfatase A activity, consistent with the
diagnosis of MLD, which thereafter was confirmed by genetic
analysis. Subsequently, a rapid deterioration of motor and
cognitive functions occurred, that was associated with drug-
resistant epilepsy on polytherapy with valproate, lamotrigine, and
levetiracetam.
At 4 years and 7months of age, bilateral thelarche was detected
at physical examination and the neurological assessment showed
spastic tetraparesis and severe intellectual disability. Family
history of precocious puberty was negative. At endocrinological
evaluation, human chorionic gonadotropin (<1.00mIU/ml),
alpha-fetoprotein (3.10 IU/ml) and carcinoembryonic antigen
(1.90 µg/L) resulted in the normal range. The hormonal
profile showed dehydroepiandrosterone sulfate in normal range
according to age (<0.4071 µmol/L), but the patient showed
moderately augmented levels of 17-Hydroxyprogesterone (5.80
nmol/L) and 17 beta-estradiol (215.51 pmol/L). Thyroid function
was normal (TSH 2.64 mIU/L, normal range 0.40–4.00 mIU/L;
FT4 12.74 pmol/L, normal range 10.30- 24.46 pmol/L; fT3 6.07
pmol/L, normal range 2.46–7.37 pmol/L). Also plasmatic levels
of valproic acid were within the normal range (517.09 µmol/L;
therapeutic range 346.71–693.43mg/L). 25-hydroxyvitamin D
Abbreviations: MLD, Metachromatic leucodystrophy; CPP, Central precocious
puberty; MRI, Magnetic resonance imaging; GnRH, Gonadotropin-releasing
hormone; CNS, Central nervous system.
was deficient (39.93 nmol/L; normal value > 74.88 nmol/L),
while 1,25-dihydroxyvitamin D3 was within the normal
range (98.40 pmol/L; normal range: 47.76–160.81 pmol/L).
Ultrasonography excluded ovarian and adrenal masses and
showed ovaries of prepubertal volume and uterus with infantile
features. X-ray of the left wrist and hand revealed a bone age of 5
years, according to Greulich and Pyle method (6). At that time,
we decided to postpone the gonadotropin-releasing hormone
(GnRH) stimulation test, given the underlying disease and the
absence of overt signs of pubertal activation.
However, at the endocrine follow-up, when the patient
was 4.8 year-old, she exhibited a progression of the pubertal
staging (Ph3 B2-3, no axillary hair), according to Marshall
and Tanner criteria (7). Ultrasonography showed a slight
increase of the uterine longitudinal diameter (42mm, normal
values <40mm) (8). She weighted 15.6 Kg [−1.31 SDS, 10th
percentile according to Cacciari et al. (9)] and was 107 cm
tall [−0.37 SDS, 25–50th percentile according to Cacciari
et al. (9)]. Due to the suspicion of CPP, we performed a
GnRH stimulation test with intravenous administration of
100 µg/m2 (maximum 100 µg) synthetic GnRH (Lutrelef 0.8
mg/10mL, FerringS,p.A., Italy) (10) that revealed a pubertal
LH peak of 12.90 IU/l. A detectable estradiol level (129.9655
pmol/L) confirmed the activation of gonadotropic axis (11).
However, an ACTH stimulation test, carried out because of
the mildly elevated value of 17-Hydroxyprogesterone, was
normal. Values of cortisol (587.58 nmol/L at 08 AM, normal
range 137.93–689.65 nmol/L) and androstenedione (3.40 nmol/L,
normal range 1.00–11.50 nmol/L) were normal. Testosterone
was undetectable (<0.6934 nmol/L). A contrast enhanced brain
MRI (Figure 1) showed a small hypophysis without focal
abnormalities, extensive symmetric areas of increased T2 signal
in the cerebral white matter including the internal capsule,
the cerebral peduncles, middle cerebellar peduncles and the
cerebellar peridentate white matter and marked brain atrophy,
consistent with MLD at an advanced stage. No contrast
enhancement of the affected white matter was observed.
Proton MR spectroscopy in the affected right parietal white
matter showed increase of the choline, a decrease of the N-
acetylasparate, and a peak of lactate (Figure 1). A diagnosis
of CPP was made and she started treatment with GnRH
agonists (triptorelin intramuscularly at a dosage of 1.875mg
every 28 days). She experienced a good response in the absence
of significant adverse effects. Accordingly, after 6 months
of therapy, a GnRH stimulation test showed a LH peak
concentration of 1.42 IU/l and a reduced value of estradiol
(80.03 pmol/L).
Laboratory Methods
All laboratory endocrinological measurements were determined
by means of chemiluminescent immunometric assays with
the use of commercially available kits for the Immulite 2000
systems analyzer (Siemens Healthcare Diagnostics). However,
17-Hydroxyprogesterone and androstenedione were assayed
by radioimmunoassay (Diagnostic systems Laboratories and
DIAsource, Nivelles, Belgium).
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FIGURE 1 | Contrast enhanced brain MRI (A–D). Axial T2 weighted FLAIR images show extensive areas of increased signal symmetrically involving the middle
cerebellar peduncles and cerebellar peridentate white matter (A) and the cerebral white matter (B,C).1H MR spectroscopy in the affected right parietal white matter
(black box in C) shows increased peaks of choline (Cho) and lactate (Lac) and decreased peak of N-acetyl-aspartate (NAA).
DISCUSSION
In MLD the accumulation of sulfatides into lysosomes of the
oligodendrocytes, Schwann cells, phagocytes, astrocytes and
neurons leads to widespread demyelination and inflammatory
changes causing apoptosis in the central and peripheral nervous
system (1, 12). MRI in MLD shows symmetric high T2 signal
intensity in the cerebral white matter, sparing subcortical U fibers
and in the corpus callosum. In more advanced stages, cerebellar
white matter, thalami and basal ganglia can be involved. Typical,
but not specific, is the so called “tigroid pattern” with radiating
stripes of normal signal intensity within the T2 hyperintense
white matter (1, 12).
Our case is peculiar because of the occurrence of CPP in a
patient suffering from a severe and rapidly progressive form of
MLD. To our knowledge, this is the first reported case of CPP
in MLD. CPP is known to occur in patients with a variety of
central nervous system (CNS) disorders (11, 13, 14), underlining
the importance of early diagnostic work-up in these patients.
Notably, review of the literature revealed a handful of cases
of inherited metabolic diseases implying damage of the brain
white matter associated with CPP or other disorders of pubertal
development (Supplementary Table 1).
For example, in mucopolysaccaridosis, a class of multi-organ
dysfunction disorders due to progressive glycosaminoglycans
accumulation, five cases of CPP were reported in patients affected
by mucopolysaccharidosis type IIIA (SanFilippo disease) (15,
16). In Hurler syndrome (mucopolysaccharidosis type IH or
MPS IH), due to α-L-iduronidase activity deficiency, CPP has
been exceptionally described in patients after hematopoietic stem
cell transplantation (17), but it is difficult to ascertain if it was an
effect of hematopoietic stem cell transplantation or was innate to
mucopolysaccharidosis type IH.
In Tay-Sachs disease, precocious puberty has been described,
probably due to hypothalamic involvement (18). A case of
CPP in a femal child of 4 years has been reported in more
detail (19). In this case, autopsy revealed storage of GM2
gangliosides in the hypothalamus but not in pituitary gland,
thus PP was attributed either to interruption of inhibitory
influences on the pituitary-gonadal axis or to lesions that
disrupt nerve endings storing LH-RH in the basal hypothalamus,
resulting in a direct stimuli for LH-RH release. The author
also suggests that the prolonged survival of patients with
storage disorders may be one the main reasons why some of
these patients have recently been described with precocious
puberty (19).
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In Phenylketonuria, two cases of CPP were reported so far. In
the former, the author suggested a toxic metabolic effect of high
serum phenylalanine levels as the trigger of premature activation
of the hypothalamic-pituitary axis (20); in the latter, values
of phenylalanine were persistently within the recommended
range, therefore the rare association was considered to be
coincidental (21).
In these reports, overall, a damage due to accumulation of
toxic metabolites in brain or in blood is frequently hypothesized
as the pathogenic mechanism leading to precocious puberty or
other premature signs of puberty, although the existence of a
causal relationship often could not be ascertained due to the
paucity of data about pubertal development in these disorders.
Admittedly, because of its rarity, the association of CPP and
MLD we observed could be coincidental. On the other hand, the
rarity of incidence of CPP in MLD could reflect the low survival
due to the severity of CNS involvement.
The onset of hypothalamic-hypophyseal-gonadal axis
function is dependent upon the highly controlled and dynamic
interactions among regulatory signals from the brain, pituitary
and gonads (22). In addition, the puberty onset also requires a
reciprocal communication neuron-glia which involves the action
of two main excitatory amino acids: glutamate and aspartate.
Besides that, some growth factors and the coordinated action
of these neuroexcitatory amino acids, and specific genes, all
of which representing a higher level of control governing the
pubertal process, are also required in order for puberty to occur
(22). So, as suggested in other diseases, we can hypothesize
that sulfatides brain accumulation in our patient may have
acted on the complex network that regulates GnRH secretion
in the diencephalon that involves kisspeptin, neurokinin B,
makorin ring finger protein 3, and others (23, 24), resulting in
an enhancement of activators and suppression of inhibitors of
gonadotropin releasing factors secretion, thus triggering puberty
initiation (23, 24). Interestingly, some authors have reported a
significant reduction of N-acetylasparate in the left dorsolateral
prefrontal cortex of a group of bipolar patients with early puberty
compared to controls (25). This aspect was reported also in our
previous research about a young girl with NF1 who developed
CCP related to a hamartoma of the tuber cinereum at 5 years of
age (26). In our case, proton MR spectroscopy showed decrease
of the N-acetylasparate, thus suggesting its possible pathogenic
role in the initiation of puberty in our patient.
However, other hypothesis may be not excluded, as well
as a concomitant role of the antiepileptic treatment in
the pathogenesis of CPP. Although the endocrine effects of
antiepileptic drugs have widely been investigated (27), only one
case of precocious puberty has been reported in a child with
myoclonic seizures treated with valproate (28). The authors
hypothesized a causal relationship based on the stabilization
of pubertal progression at withdrawal of valproate without
any hormonal treatment. However they also suggested that
epilepsy and CPP could be primitively associated. Indeed, a
relationship between idiopathic CPP and not specific organic
and functional alterations of CNS, disrupting the hypothalamic-
pituitary-gonadal axis, has been postulated (28, 29).
CONCLUDING REMARKS
In conclusion, we report the first case of CPP occurrence in
a patient affected by MLD. Although several CNS diseases
including inherited metabolic diseases causing damage to the
brain white matter can be associated with CPP or delayed
puberty, the pathogenic link between these conditions and
CPP is obscure. Nevertheless, our case underlines the possible
occurrence of CPP, even in the first years of life, in patients
suffering from neuro metabolic disorders; therefore, it suggests
that pediatricians should be aware of this possibility and evaluate
pubertal stage on a routine basis during follow up visits,
referring patients to a pediatric endocrinologist and endocrine
work up if any signs of pubertal development occurred. Larger
multicenter studies are needed, enrolling patients suffering from
MLD with different disease severity, despite the early death of
some of these, to assess the time of onset of puberty in this
population and to better clarify the relationship between MLD
and CPP.
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